Cabopre: Phase Ii Study Of Cabozantinib Prior To Cytoreductive Nephrectomy (Cn) In Locally Advanced And/Or Metastatic Renal Cell Carcinoma (Mrcc).

TPS4603Background: Cabozantinib is a small molecule tyrosine kinase inhibitor (TKI) of VEGFR2, MET and AXL that has shown a statistically significant improvement for mRCC patients in all three endpoints of clinical efficacy (objective response rate [ORR], progression free survival [PFS], and overall survival [OS]) in a phase III randomized trial compared to everolimus, as well as a significant clinical benefit in PFS and ORR over sunitinib as first-line therapy in patients with IMDC intermediate- or poor-risk. Although no robust evidence is available, CN remains as the standard of care in patients who will be treated with VEGF TKI. CABOPRE is a multicenter, non-randomized, uncontrolled phase II trial that evaluates the efficacy and safety of cabozantinib as perioperative therapy in patients with advanced RCC who are candidates for CN. Methods: Eligible patients are aged ≥ 18 years, mRCC with a component of clear cell, suitable for CN with acceptable risk for surgery, PS 0-1, no prior systemic therapy. Cab...